State of the art of the therapeutic perspective of Sorafenib against hematological malignancies

Current Medicinal Chemistry

Volumn 19, Issue 28, 2012, Pages 4875-4884

  Zauli, G ^a   Voltan, R ^b   Tisato, V ^b   Secchiero, P ^b  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Acute Myeloid Leukemia; B Chronic Lymphocytic Leukemia; Bcl 2; ERK pathway; FLT3 ITD; Hematological malignancies; Innovative drug combinations; Kinase inhibitor; Leukemia; Mcl 1; Sorafenib

Indexed keywords

AZACITIDINE; BORTEZOMIB; CLOFARABINE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; LENALIDOMIDE; MITOXANTRONE; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; NUTLIN 3; OBATOCLAX; PLERIXAFOR; PROTEIN MDM2; RAF PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SORAFENIB; VASCULOTROPIN RECEPTOR; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG STRUCTURE; FATIGUE; GENE MUTATION; GENETIC PARAMETERS; HAND FOOT SYNDROME; HEMATOLOGIC MALIGNANCY; HUMAN; INTERNAL TANDEM DUPLICATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; MEDLINE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; PLASMACYTOMA; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

APOPTOSIS; CLINICAL TRIALS AS TOPIC; FMS-LIKE TYROSINE KINASE 3; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84870414970     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803341548     Document Type: Article

References (110)

1. Lyons, J.F.; Wilhelm, S.; Hibner, B.; Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer, 2001, 8, 219-225
2. Sebolt-Leopold, J.S.; Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer, 2004, 4, 937-947
3. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L.E.; Bollag, G.; Trail, P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64, 7099-7109
4. Carlomagno, F.; Anaganti, S.; Guida, T.; Salvatore, G.; Troncone, G.; Wilhelm, S.M.; Santoro, M. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst., 2006, 98, 326-334
5. Pratz, K.W.; Levis, M.J. Bench to bedside targeting of FLT3 in acute leukemia. Curr. Drug Targets, 2010, 11, 781-789
6. Johnson, L.N. Protein kinase inhibitors: contributions from structure to clinical compounds. Q. Rev. Biophys., 2009, 42, 1-40
7. Wan, P.T.; Garnett, M.J.; Roe, S.M.; Lee, S.; Niculescu-Duvaz, D.; Good, V.M.; Jones, C.M.; Marshall, C.J.; Springer, C.J.; Barford, D.; Marais, R.; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004, 116, 855-67
8. Yao, J.; Chen, J.; He, Z.; Sun, W.; Xu, W. Design, synthesis and biological activities of thiourea containing sorafenib analogs as antitumor agents. Bioorg. Med. Chem., 2012, 20, 2923-9
9. Sun, M.; Wu, X.; Chen, J.; Cai, J.; Cao, M.; Ji, M. Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives. Eur. J. Med. Chem., 2010, 45, 2299-306
10. Potashman, M.H.; Bready, J.; Coxon, A.; DeMelfi, T.M. Jr; DiPietro, L.; Doerr, N.; Elbaum, D.; Estrada, J.; Gallant, P.; Germain, J.; Gu, Y.; Harmange, J.C.; Kaufman, S.A.; Kendall, R.; Kim, J.L.; Kumar, G.N.; Long, A.M.; Neervannan, S.; Patel, V.F.; Polverino, A.; Rose, P.; Plas, S.; Whittington, D.; Zanon, R.; Zhao, H. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J. Med. Chem., 2007, 50, 4351-73
11. Zhang, W.; Konopleva, M.; Shi, Y.X.; McQueen, T.; Harris, D.; Ling, X.; Estrov, Z.; Quintás-Cardama, A.; Small, D.; Cortes, J.; Andreeff, M. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl. Cancer Inst., 2008, 100, 184-198
12. Lierman, E.; Lahortiga, I.; Van Miegroet, H.; Mentens, N.; Marynen, P.; Cools, J. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica, 2007, 92, 27-34
13. Auclair, D.; Miller, D.; Yatsula, V.; Pickett, W.; Carter, C.; Chang, Y.; Zhang, X.; Wilkie, D.; Burd, A.; Shi, H.; Rocks, S.; Gedrich, R.; Abriola, L.; Vasavada, H.; Lynch, M.; Dumas, J.; Trail, P.A.; Wilhelm, S.M. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia, 2007, 21, 439-445
14. Safaian, N.N.; Czibere, A.; Bruns, I.; Fenk, R.; Reinecke, P.; Dienst, A.; Haas, R.; Kobbe, G. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk. Res., 2009, 33, 348-350
15. Stirewalt, D.L.; Radich, J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer, 2003, 3, 650-665
16. Nakao, M.; Yokota, S.; Iwai, T.; Kaneko, H.; Horiike, S.; Kashima, K.; Sonoda, Y.; Fujimoto, T.; Misawa, S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 1996, 10, 1911-1918
17. Yamamoto, Y.; Kiyoi, H.; Nakano, Y.; Suzuki, R.; Kodera, Y.; Miyawaki, S.; Asou, N.; Kuriyama, K.; Yagasaki, F.; Shimazaki, C.; Akiyama, H.; Saito, K.; Nishimura, M.; Motoji, T.; Shinagawa, K.; Takeshita, A.; Saito, H.; Ueda, R.; Ohno, R.; Naoe, T. Activating mutation of D835 within the activation loop of FLT3 in human hematological malignancies. Blood, 2001, 97, 2434-2439
18. Yanada, M.; Matsuo, K.; Suzuki, T.; Kiyoi, H.; Naoe, T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a metaanalysis. Leukemia, 2005, 19, 1345-1349
19. Whitman, S.P.; Ruppert, A.S.; Radmacher, M.D.; Mrozek, K.; Paschka, P.; Langer, C.; Baldus, C.D.; Wen, J.; Racke, F.; Powell, B.L.; Kolitz, J.E.; Larson, R.A.; Caligiuri, M.A.; Marcucci, G.; Bloomfield, C.D. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct geneexpression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood, 2008, 111, 1552-1559
20. Radomska, H.S.; Basseres, D.S.; Zheng, R.; Zhang, P.; Dayaram, T.; Yamamoto, Y.; Sternberg, D.W.; Lokker, N.; Giese, N.A.; Bohlander, S.K.; Schnittger, S.; Delmotte, M.H.; Davis, R.J.; Small, D.; Hiddemann, W.; Gilliland, D.G.; Tenen, D.G. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J. Exp. Med., 2006, 203, 371-381
21. Mizuki, M.; Fenski, R.; Halfter, H.; Matsumura, I.; Schmidt, R.; Müller, C.; Grüning, W.; Kratz-Albers, K.; Serve, S.; Steur, C.; Büchner, T.; Kienast, J.; Kanakura, Y.; Berdel, W.E.; Serve, H. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood, 2000, 96, 3907-3914
22. Choudhary, C.; Brandts, C.; Schwable, J.; Tickenbrock, L.; Sargin, B.; Ueker, A.; Böhmer, F.D.; Berdel, W.E.; Müller-Tidow, C.; Serve, H. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood, 2007, 110, 370-374
23. Warr, M.R.; Shore, G.C. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr. Mol. Med., 2008, 8, 138-147
24. Aichberger, K.J.; Mayerhofer, M.; Krauth, M.T.; Skvara, H.; Florian, S.; Sonneck, K.; Akgul, C.; Derdak, S.; Pickl, W.F.; Wacheck, V.; Selzer, E.; Monia, B.P.; Moriggl, R.; Valent, P.; Sillaber, C. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood, 2005, 105, 3303-3311
25. Borthakur, G.; Kantarjian, H.; Ravandi, F.; Zhang, W.; Konopleva, M.; Wright, J.J.; Faderl, S.; Verstovsek, S.; Mathews, S.; Andreeff, M.; Cortes, J.E. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica, 2011, 96, 62-68
26. Metzelder, S.; Wang, Y.; Wollmer, E.; Wanzel, M.; Teichler, S.; Chaturvedi, A.; Eilers, M.; Enghofer, E.; Neubauer, A.; Burchert, A. Compassionate use of sorafenib in FLT3-ITD positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood, 2009, 113, 6567-6571
27. Mohan, B.P.; How, G.F.; Loh, Y.; Linn, Y.C. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia. Br. J. Haematol., 2011, Nov 3. doi: 10.1111
28. Sharma, M.; Ravandi, F.; Bayraktar, U.D.; Chiattone, A.; Bashir, Q.; Giralt, S.; Chen, J.; Qazilbash, M.; Kebriaei, P.; Konopleva, M.; Andreeff, M.; Cortes, J.; McCue, D.; Kantarjian, H.; Champlin, R.E.; de Lima, M. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol. Blood Marrow Transplant., 2011, 17, 1874-1877
29. Sorà, F.; Chiusolo, P.; Metafuni, E.; Bellesi, S.; Giammarco, S.; Laurenti, L.; Ausoni, G.; Zini, G.; Bayer, A.J., Mario, B.; Leone, G.; Sica, S. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. Leuk. Res., 2011, 35, 422-423
30. Schroeder, T.; Zohren, F.; Saure, C.; Bruns, I.; Czibere, A.; Safaian, N.N.; Fenk, R.; Haas, R.; Kobbe, G. Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy. Acta Haematol., 2010, 124, 153-159
31. Winkler, J.; Rech, D.; Kallert, S.; Rech, J.; Meidenbauer, N.; Roesler, W.; Mackensen, A. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report. Leuk. Res., 2010, 34, e270-e272
32. Röllig, C.; Brandts, C.; Shaid, S.; Hentrich, M.; Krämer, A.; Junghanß, C.; Schleyer, E.; Müller-Tidow, C.; Berdel, W.E.; Ritter, B.; Pflüger, K.H.; Kramer, M.; Haibach, M.; Ehninger, G.; Serve, H.; Krause, S.W. Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. Leuk. Lymphoma, 2011, Dec 7 [Epub ahead of print]
33. Scholl, S.; Spies-Weisshart, B.; Klink, A.; Muegge, L.O.; Fricke, H.J.; Hochhaus, A. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. Ann. Hematol., 2011, 90, 473-475
34. Pratz, K.W.; Cho, E.; Levis, M.J.; Karp, J.E.; Gore, S.D.; McDevitt, M.; Stine, A.; Zhao, M.; Baker, S.D.; Carducci, M.A.; Wright, J.J.; Rudek, M.A.; Smith, B.D. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia, 2010, 24, 1437-1444
35. Pratz, K.W.; Sato, T.; Murphy, K.M.; Stine, A.; Rajkhowa, T.; Levis, M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood, 2010, 115, 1425-1432
36. Man, C.H.; Fung, T.K.; Ho, C.; Han, H.H.; Chow, H.C.; Ma, A.C.; Choi, W.W.; Lok, S.; Cheung, A.M.; Eaves, C.; Kwong, Y.L.; Leung, A.Y. Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness associated with a D835 mutation. Blood, 2012, Feb 24 [Epub ahead of print]
37. Sato, T.; Yang, X.; Knapper, S.; White, P.; Smith, B.D.; Galkin, S.; Small, D.; Burnett, A.; Levis, M. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood, 2011, 117, 3286-3293
38. Parmar, A.; Marz, S.; Rushton, S.; Holzwarth, C.; Lind, K.; Kayser, S.; Döhner, K.; Peschel, C.; Oostendorp, R.A.; Götze, K.S. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors. Cancer Res., 2011, 71, 4696-4706
39. Secchiero, P.; di Iasio, M.G.; Gonelli, A.; Zauli, G. The MDM2 inhibitors Nutlins as an innovative therapeutic tool for the treatment of hematological malignancies. Curr. Pharmac. Des., 2008, 14, 2100-2110
40. Kojima, K.; Konopleva, M.; Samudio, I.J.; Shikami, M.; Cabreira-Hansen, M.; McQueen, T.; Ruvolo, V.; Tsao, T.; Zeng, Z.; Vassilev, L.T.; Andreeff M. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood, 2005, 106, 3150-3159
41. Secchiero, P.; Zerbinati, C.; Melloni, E.; Milani, D.; Campioni, D.; Fadda, R.; Tiribelli, M.; Zauli, G. The MDM-2 antagonist Nutlin-3 promotes maturation of acute myeloid leukemic blasts. Neoplasia, 2007, 9, 853-861
42. Secchiero, P.; Zerbinati, C.; di Iasio, M.G.; Melloni, E.; Tiribelli, M.; Grill, V.; Zauli, G. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr. Drug Metab., 2007, 8, 395-403
43. Secchiero, P.; Melloni, E.; di Iasio, M.G.; Tiribelli, M.; Rimondi, E.; Corallini, F.; Gattei, V.; Zauli, G. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood, 2009, 113, 4300-4308
44. Long, J.; Parkin, B.; Ouillette, P.; Bixby, D.; Shedden, K.; Erba, H., Wang, S.; Malek, S.N. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood, 2010, 116, 71-80
45. Wergeland, L.; Sjøholt, G.; Haaland, I.; Hovland, R.; Bruserud, ø.; Gjertsen, B.T. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Mol. Cancer, 2007, 6, 33
46. Vatsyayan, R.; Singhal, J.; Nagaprashantha, L.D.; Awasthi, S.; Singhal, S.S. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma. Mol. Carinog., 2001, Oct 17. doi: 10.1002/mc.20875 [Epub ahead of print]
47. Haouala, A.; Zanolari, B.; Rochat, B.; Montemurro, M.; Zaman, K.; Duchosal, M.A.; Ris, H.B., Leyvraz, S., Widmer, N., Decosterd, L.A. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2009, 877, 1982-1996
48. Clark, J.W.; Eder, J.P.; Ryan, D.; Lathia, C.; Lenz, H.J. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res., 2005, 11, 5472-5480
49. Strumberg, D.; Clark, J.W.; Awada, A.; Moore, M.J.; Richly, H.; Hendlisz, A.; Hirte, H.W.; Eder, J.P.; Lenz, H.J.; Schwartz, B. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist, 2007, 12, 426-437
50. Kojima, K.; Konopleva, M.; Tsao, T.; Andreeff, M.; Ishida, H.; Shiotsu, Y.; Jin, L.; Tabe, Y.; Nakakuma, H. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Leukemia, 2010, 24, 33-43
51. Tseng, H.Y.; Jiang, C.C.; Croft, A.; Tay, K.H.; Thorne, R.F.; Yang, F.; Liu, H.; Hersey, P.; Zhang, X.D. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells. Mol. Cancer Ther., 2010, 9, 3363-3374
52. Kondo, Y.; Kanzawa, T.; Sawaya, R.; Kondo, S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer, 2005, 5, 726-734
53. Germain, M.; Slack, R.S. Mcl-1 regulates the balance between autophagy and apoptosis. Autophagy, 2011, 7, 549-551
54. Secchiero, P.; Melloni, E.; Voltan, R.; Norcio, A.; Celeghini, C.; Zauli, G. MCL1 down-regulation plays a critical role in mediating the higher antileukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. Br. J. Haematol., 2012, doi: 10.1111/j.1365-2141.2012.09042
55. Inuzuka, H., Fukushima, H., Shaik, S.; Liu, P.; Lau, A.W.; Wei, W. Mcl-1 ubiquitination and destruction. Oncotarget, 2011, 2, 239-244
56. Yoshimoto, G.; Miyamoto, T.; Jabbarzadeh-Tabrizi, S.; Iino, T.; Rocnik, J.L.; Kikushige, Y.; Mori, Y.; Shima, T.; Iwasaki, H.; Takenaka, K.; Nagafuji, K.; Mizuno, S.; Niiro, H.; Gilliland, G.D.; Akashi, K. FLT3-ITD upregulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood, 2009, 114, 5034-5043
57. Yokota, S.; Kiyoi, H.; Nakao, M.; Iwai, T.; Misawa, S.; Okuda, T.; Sonoda, Y.; Abe, T.; Kahsima, K.; Matsuo, Y.; Naoe, T. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia, 1997, 11, 1605-1609
58. Park, M.A.; Reinehr, R.; Hussinger, D.; Voelkel-Johnson, C.; Ogretmen, B.; Yacoub, A.; Grant, S.; Dent, P. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol. Cancer Ther., 2010, 9, 2220-2231
59. Martin, A.P.; Mitchell, C.; Rahmani, M.; Nephew, K.P.; Grant, S.; Dent, P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol. Ther., 2009, 8, 2084-2096
60. Zhang, W.; Konopleva, M.; Ruvolo, V.R.; McQueen, T.; Evans, R.L.; Bornmann, W.G.; McCubrey, J.; Cortes, J.; Andreeff, M. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia, 2008, 22, 808-818
61. Hu, S.; Niu, H.; Inaba, H.; Orwick, S.; Rose, C.; Panetta, J.C.; Yang, S.; Pounds, S.; Fan, Y.; Calabrese, C.; Rehg, J.E.; Campana, D.; Rubnitz, J.E.; Baker, S.D. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J. Natl. Cancer Inst., 2011, 103, 893-905
62. Rahmani, M.; Aust, M.M.; Attkisson, E.; Williams, D.C.Jr; Ferreira-Gonzalez, A.; Grant, S. Inhibition of Bcl-2 anti-apoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood, 2012, Mar 23 [Epub ahead of print]
63. Al-Kali, A.; Cortes, J.; Faderl, S.; Jones, D.; Abril, C.; Pierce, S.; Brandt, M.; Kantarjian, H.; Ravandi, F. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin. Lymphoma Myeloma Leuk., 2011, 11, 361-366
64. Ravandi, F.; Cortes, J.E.; Jones, D.; Faderl, S.; Garcia-Manero, G.; Konopleva, M.Y.; O'Brien, S.; Estrov, Z.; Borthakur, G.; Thomas, D.; Pierce, S.R.; Brandt, M.; Byrd, A.; Bekele, B.N.; Pratz, K.; Luthra, R.; Levis, M.; Andreeff, M.; Kantarjian, H.M. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J. Clin. Oncol., 2010, 28, 1856-1862
65. Watt, T.C.; Cooper, T. Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. Pediatr. Blood Cancer, 2011, Nov 2
66. Inaba, H.; Rubnitz, J.E.; Coustan-Smith, E.; Li, L.; Furmanski, B.D.; Mascara, G.P.; Heym, K.M.; Christensen, R.; Onciu, M.; Shurtleff, S.A.; Pounds, S.B.; Pui, C.H.; Ribeiro, R.C.; Campana, D.; Baker, S.D. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/ refractory leukemia. J. Clin. Oncol., 2011, 29, 3293-3300
67. Pui, C.H.; Carroll, W.L.; Meshinchi, S.; Arceci, R.J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol., 2011, 29, 551-565
68. Ross, J.A.; Linabery, A.M.; Blommer, C.N.; Langer, E.K.; Spector, L.G.; Hilden, J.M.; Heerema, N.A.; Radloff, G.A.; Tower, R.L.; Davies, S.M. Genetic variants modify susceptibility to leukemia in infants: a children's oncology group report. Pediatr. Blood Cancer, 2012, Mar 15. doi: 10.1002/pbc.24131
69. Lane, S.W.; Wang, Y.J.; Lo Celso, C.; Ragu, C.; Bullinger, L.; Sykes, S.M.; Ferraro, F.; Shterental, S.; Lin, C.P.; Gilliland, D.G.; Scadden, D.T.; Armstrong, S.A.; Williams, D.A. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood, 2011, 118, 2849-2856
70. Zeng, Z.; Shi, Y.X.; Samudio, I.J.; Wang, R.Y.; Ling, X.; Frolova, O.; Levis, M.; Rubin, J.B.; Negrin, R.R.; Estey, E.H.; Konoplev, S.; Andreeff, M.; Konopleva, M. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood, 2009, 113, 6215-6224
71. Di Pietro, R.; Zauli, G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J. Cell. Physiol., 2004, 201, 331-340
72. Volpato, S.; Ferrucci, L.; Secchiero, P.; Corallini, F.; Zuliani, G.; Fellin, R.; Guralnik, J.M.; Bandinelli, S.; Zauli, G. Association of tumor necrosis factor- relatd apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis, 2011, 215, 452-458
73. Zauli, G.; Melloni, E.; Capitani, S.; Secchiero, P. Role of full-length osteoprotegerin in tumor cell biology. Cell. Mol. Life Sci., 2009, 66, 841-851
74. Hellwig, C.T.; Rehm, M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol. Cancer Ther., 2012, 11, 3-13
75. Grosse-Wilde, A.; Voloshanenko, O.; Bailey, S.L.; Longton, G.M.; Schaefer, U.; Csernok, A.I.; Schütz, G.; Greiner, E.F.; Kemp, C.J.; Walczak, H. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J. Clin. Invest., 2008, 118, 100-110
76. Malin, D.; Chen, F.; Schiller, C.; Koblinski, J.; Cryns, V.L. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triplenegative breast cancer. Clin. Cancer Res., 2011, 17, 5005-5015
77. Zauli, G.; Bosco, R.; Secchiero, P. Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opin. Ther. Targets, 2011, 15, 931-942
78. Tazzari, P.L.; Tabellini, G.; Ricci, F.; Papa, V.; Bortul, R.; Chiarini, F.; Evangelisti, C.; Martinelli, G.; Bontadini, A.; Cocco, L.; McCubrey, J.A.; Martelli, A.M. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res., 2008, 68, 9394-403
79. Carter, B.Z.; Mak, D.H.; Schober, W.D.; Dietrich, M.F.; Pinilla, C.; Vas-silev, L.T.; Reed, J.C.; Andreeff, M. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood, 2008, 111, 3742-3750
80. Chamuleau, M.E.; Ossenkoppele, G.J.; van Rhenen, A.; van Dreunen, L.; Jirka, S.M.; Zevenbergen, A.; Schuurhuis, G.J.; van de Loosdrecht, A.A. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk. Res., 2011, 35, 741-749
81. Secchiero, P.; Zauli, G. TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr. Op. Hematol., 2008, 15, 42-48
82. Rosato, R.R.; Almenara, J.A.; Coe, S.; Grant, S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res., 2007, 67, 9490-9500
83. Meng, X.W.; Lee, S.H.; Dai, H.; Loegering, D.; Yu, C.; Flatten, K.; Schneider, P.; Dai, N.T.; Kumar, S.K.; Smith, B.D.; Karp, J.E.; Adjei, A.A.; Kaufmann, S.H. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J. Biol. Chem., 2007, 282, 29831-29846
84. Jacquemin, G.; Granci, V.; Gallouet, A.S.; Lalaoui, N.; Morlé, A.; Iessi, E.; Morizot, A.; Garrido, C.; Guillaudeux, T.; Micheau, O. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica, 2012, 97, 38-46
85. Messmer, D.; Fecteau, J.F.; O'Hayre, M.; Bharati, I.S.; Handel, T.M.; Kipps, T.J. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood, 2011, 117, 882-889
86. López-Guerra, M.; Xargay-Torrent, S.; Pérez-Galán, P.; Saborit-Villarroya, I.; Rosich, L.; Villamor, N.; Aymerich, M.; Roué, G.; Campo, E.; Montserrat, E.; Colomer, D. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. Leukemia, 2011, Dec 20. doi: 10.1038/leu.2011.364
87. Fecteau, J.F.; Bharati, I.S.; O'Hayre, M.; Handel, T.M.; Kipps, T.J.; Messmer, D. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol. Med., 2012, 18, 19-28
88. Huber, S.; Oelsner, M.; Decker, T.; zum Büschenfelde, C.M.; Wagner, M.; Lutzny, G.; Kuhnt, T.; Schmidt, B.; Oostendorp, R.A.; Peschel, C.; Ringshausen, I. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia, 2011, 25, 838-847
89. Crump, M.; Hedley, D.; Kamel-Reid, S.; Leber, B.; Wells, R.; Brandwein, J.; Buckstein, R.; Kassis, J.; Minden, M.; Matthews, J.; Robinson, S.; Turner, R.; McIntosh, L.; Eisenhauer, E.; Seymour, L. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk. Lymphoma, 2010, 51, 252-260
90. Mori, M.; Sprague, J. The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics. Leuk. Res., 2012, 36, e1-3
91. Wakim, J.J.; Tirado, C.A.; Chen, W.; Collins, R. t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with Sorafenib and review of the literature. Leuk. Res., 2011, 35, e151-e153
92. Inuzuka, H.; Shaik, S.; Onoyama, I.; Gao, D.; Tseng, A.; Maser, R.S.; Zhai, B.; Wan, L.; Gutierrez, A.; Lau, A.W.; Xiao, Y.; Christie, A.L.; Aster, J.; Settleman, J.; Gygi, S.P.; Kung, A.L.; Look, T.; Nakayama, K.I.; DePinho, R.A.; Wei, W. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature, 2011, 471, 104-109
93. Inuzuka, H.; Fukushima, H.; Shaik, S.; Liu, P.; Lau, A.W.; Wei, W. Mcl-1 ubiquitination and destruction. Oncotarget, 2011, 2, 239-244
94. Schult, C.; Dahlhaus, M.; Ruck, S.; Sawitzky, M.; Amoroso, F.; Lange, S.; Etro, D.; Glass, A.; Fuellen, G.; Boldt, S.; Wolkenhauer, O.; Neri, L.M.; Freund, M.; Junghanss, C. The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. BMC Cancer, 2010, 10, 560
95. Ramakrishnan, V.; Timm, M.; Haug, J.L.; Kimlinger, T.K.; Halling, T.; Wellik, L.E.; Witzig, T.E.; Rajkumar, S.V.; Adjei, A.A.; Kumar, S. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am. J. Hematol., 2012, 87, 277-283
96. af Gennäs, G.B.; Mologni, L.; Ahmed, S.; Rajaratnam, M.; Marin, O.; Lindholm, N.; Viltadi, M.; Gambacorti-Passerini, C.; Scapozza, L.; Yli- Kauhaluoma, J. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors. Chem. Med. Chem., 2011, 6, 1680-1692
97. Walz, C.; Erben, P.; Ritter, M.; Bloor, A.; Metzgeroth, G.; Telford, N.; Haferlach, C.; Haferlach, T.; Gesk, S.; Score, J.; Hofmann, W.K.; Hochhaus, A.; Cross, N.C.; Reiter, A. Response of ETV6-FLT3-positive myeloid/ lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood, 2011, 118, 2239-2242
98. Chapuy, B.; Schuelper, N.; Panse, M.; Dohm, A.; Hand, E.; Schroers, R.; Truemper, L.; Wulf, G.G. Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. Br. J. Haematol., 2011, 152, 401-412
99. Ullrich, K.; Wurster, K.D.; Lamprecht, B.; Köchert, K.; Engert, A.; Dörken, B.; Janz, M.; Mathas, S. BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines. Br. J. Haematol., 2011, 155, 398-402
100. Ambrosini, V.; Quarta, C.; Zinzani, P.L.; Nanni, C.; Fini, M.; Torricelli, P.; Giavaresi, G.; D'Errico-Grigioni, A.; Malvi, D.; Franchi, R.; Fanti, S. 18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models. Q. J. Nuc.l Med. Mol. Imaging., 2010, 54, 689-697
101. Cheng, A.L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; Xu, J.; Sun, Y.; Liang, H.; Liu, J.; Wang, J.; Tak, W.Y.; Pan, H.; Burock, K.; Zou, J.; Voliotis, D.; Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol., 2009, 10, 25-34
102. Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Staehler, M.; Negrier, S.; Chevreau, C.; Desai, A.A.; Rolland, F.; Demkow, T.; Hutson, T.E.; Gore, M.; Anderson, S.; Hofilena, G.; Shan, M.; Pena, C.; Lathia, C.; Bukowski, R.M. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol., 2009, 27, 3312-3318
103. Hauschild, A.; Agarwala, S.S.; Trefzer, U.; Hogg, D.; Robert, C.; Hersey, P.; Eggermont, A.; Grabbe, S.; Gonzalez, R.; Gille, J.; Peschel, C.; Schadendorf, D.; Garbe, C.; O'Day, S.; Daud, A.; White, J.M.; Xia, C.; Patel, K.; Kirkwood, J.M.; Keilholz, U. Results of a phase III, randomized, placebocontrolled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol., 2009, 27, 2823-2830
104. Hoffmann, K.; Glimm, H.; Radeleff, B.; Richter, G.; Heining, C.; Schenkel, I.; Zahlten-Hinguranage, A.; Schirrmacher, P.; Schmidt, J.; Büchler, M.W.; Jaeger, D.; von Kalle, C.; Schemmer, P. Prospective, randomized, doubleblind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer, 2008, 8, 349
105. Hutson, T.E. Safety and tolerability of Sorafenib in clear-cell renal cell carcinoma: a phase III overview. Expert. Rev. Anticancer. Ther., 2007, 7, 1193-1202
106. Strumberg, D.; Voliotis, D.; Moeller, J.G.; Hilger, R.A.; Richly, H.; Kredtke, S.; Beling, C.; Scheulen, M.E.; Seeber, S. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int. J. Clin. Pharmacol. Ther., 2002, 40, 580-581
107. Porta, C.; Paglino, C.; Imarisio, I.; Bonomi, L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin. Exp. Med., 2007, 7, 127-134
108. Blanchet, B.; Billemont, B.; Barete, S.; Garrigue, H.; Cabanes, L.; Coriat, R.; Frances, C.; Knebelmann, B.; Goldwasser, F. Toxicity of sorafenib: clinical and molecular aspects. Expert Opin. Drug Saf., 2010, 9, 275-287
109. Schutz, F.A.; Je, Y.; Choueiri, T.K. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. Crit. Rev. Oncol. Hematol., 2011, 80, 291-300
110. Fesler, M.J. Marked bone marrow hypoplasia associated with sorafenibinduced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia. Leuk. Res., 2011, 35, e21-22